Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

October 27, 2025 09:22 ET | Source: Clearmind Medicine Inc.

Clearmind Medicine Appoints Mary-Elizabeth Gifford as Chief of Global Impact to Advance US Partnerships and Governmental Engagement

Vancouver, Canada, Oct. 27, 2025 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (Nasdaq: CMND), (FSE: CWY0) (“Clearmind” or the "Company"), a clinical-stage biotech company focused on discovery and...
October 21, 2025 07:00 ET | Source: Kailera Therapeutics, Inc.

Hengrui Pharma and Kailera Therapeutics Announce Phase 3 HRS9531 Obesity Data Presentation at ObesityWeek® 2025

Hengrui Pharma and Kailera today announced an oral presentation of HRS9531 Phase 3 data at ObesityWeek® 2025, the annual meeting of the Obesity Society.
October 20, 2025 07:41 ET | Source: Clearmind Medicine Inc.

Clearmind Medicine Announces Publication of U.S. Patent Application Targeting Binge Behavior Disorders

Vancouver, Canada, Oct. 20, 2025 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (Nasdaq: CMND), (FSE: CWY0) (“Clearmind” or the "Company"), a clinical-stage biotech company focused on discovery and...
October 14, 2025 08:00 ET | Source: CYTOMED THERAPEUTICS LIMITED

CytoMed makes cash bid for potential acquisition of TC BioPharm Limited’s relevant assets

SINGAPORE, Oct. 14, 2025 (GLOBE NEWSWIRE) -- CytoMed Therapeutics Limited (NASDAQ: GDTC) (“CytoMed” or “Company”), a Singapore-based clinical stage biopharmaceutical company focused on harnessing...
October 14, 2025 06:30 ET | Source: Kailera Therapeutics, Inc.

Kailera Therapeutics Announces $600 Million Series B Financing to Further Advance Pipeline of Next-Generation Therapies for the Treatment of Obesity

Kailera Therapeutics announced a $600M Series B financing led by new investor Bain Capital Private Equity to support its late-stage obesity portfolio.
October 08, 2025 07:09 ET | Source: Nilo Therapeutics

Nilo Therapeutics launches with $101 million Series A financing to advance a new class of medicines targeting neural circuits in immune disease and appoints Kim Seth as Chief Executive Officer

Nilo Therapeutics launches with $101 million Series A to target neural circuits in immune disease and appoints Kim Seth as Chief Executive Officer
October 07, 2025 10:30 ET | Source: Precedence Research

Digital Therapeutics Market Size to Lead USD 56.76 Bn by 2034 Driven by Digital Therapeutics, Cost Control, and Chronic Disease Prevalence

Ottawa, Oct. 07, 2025 (GLOBE NEWSWIRE) -- According to Statifacts, the global digital therapeutics market size reached USD 7.88 billion in 2024 and is estimated to attain USD 56.76 billion by 2034,...
September 16, 2025 13:00 ET | Source: UTR Therapeutics Inc.

UTR Therapeutics Publishes Landmark Preclinical Data in Frontiers in Pharmacology Supporting IND Submission for First-in-Class c-MYC RNA Therapeutic

UTR Therapeutics Inc Publishes Data supporting US FDA IND for a First-in-Human Clinical Trial of mRNA destabilizing drug targeting c-MYC driven cancer
September 11, 2025 09:00 ET | Source: Precedence Research

Anti-Obesity Drugs Market Size Drives at 27.04% CAGR by 2034

Ottawa, Sept. 11, 2025 (GLOBE NEWSWIRE) -- The global anti-obesity drugs market size was valued at USD 7.17 billion in 2024 and is predicted to hit around USD 78.46 billion by 2034, rising at a...
September 04, 2025 11:00 ET | Source: Precedence Research

Monoclonal Antibodies Therapeutics Market Size Projected to Reach USD 1,057.91 Billion by 2034

Ottawa, Sept. 04, 2025 (GLOBE NEWSWIRE) -- The global monoclonal antibody therapeutics market size was estimated at USD 265.17 billion in 2024 and is projected to reach approximately USD 1,057.91...